Alethia Biotherapeutics to present at the 12th Annual Discovery on Target conference at the Westin Boston Waterfront, Boston, MA. Dr. Mario Filion, Chief Scientific Officer, will be a speaker during the Antibodies Against Membrane Protein Targets session on October 9: “Targeting Siglec-15 for Therapeutic Inhibition of Osteoclastic Bone Resorption Results in the Maintenance of Bone Formation”.
